Dowling & Yahnke’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $5.46M | Buy |
12,014
+134
| +1% | +$64.1K | 0.25% | 97 |
|
|
2022
Q2 | $5.73M | Sell |
11,880
-8
| -0.1% | -$3.96K | 0.27% | 96 |
|
|
2022
Q1 | $5.84M | Buy |
11,888
+239
| +2% | +$109K | 0.25% | 102 |
|
|
2021
Q4 | $5.4M | Buy |
11,649
+251
| +2% | +$106K | 0.26% | 106 |
|
|
2021
Q3 | $4.25M | Buy |
11,398
+234
| +2% | +$88.9K | 0.24% | 116 |
|
|
2021
Q2 | $4.26M | Buy |
11,164
+572
| +5% | +$219K | 0.24% | 108 |
|
|
2021
Q1 | $3.8M | Buy |
10,592
+185
| +2% | +$59.5K | 0.26% | 108 |
|
|
2020
Q4 | $3.34M | Sell |
10,407
-19
| -0.2% | -$5.83K | 0.24% | 113 |
|
|
2020
Q3 | $2.8M | Buy |
10,426
+112
| +1% | +$30.1K | 0.22% | 120 |
|
|
2020
Q2 | $2.71M | Buy |
10,314
+1,629
| +19% | +$435K | 0.23% | 116 |
|
|
2020
Q1 | $1.97M | Buy |
8,685
+34
| +0.4% | +$9.27K | 0.19% | 134 |
|
|
2019
Q4 | $2.61M | Buy |
8,651
+266
| +3% | +$73.2K | 0.2% | 130 |
|
|
2019
Q3 | $2.01M | Sell |
8,385
-20
| -0.2% | -$5.48K | 0.17% | 138 |
|
|
2019
Q2 | $2.37M | Buy |
+8,405
| New | +$2.3M | 0.2% | 129 |
|
|
2018
Q4 | – | Sell |
-7,617
| Closed | -$2.09M | – | 269 |
|
|
2018
Q3 | $2.09M | Buy |
7,617
+35
| +0.5% | +$9.09K | 0.18% | 141 |
|
|
2018
Q2 | $1.8M | Sell |
7,582
-15
| -0.2% | -$3.47K | 0.17% | 154 |
|
|
2018
Q1 | $1.67M | Buy |
7,597
+152
| +2% | +$35.7K | 0.16% | 158 |
|
|
2017
Q4 | $1.68M | Buy |
7,445
+241
| +3% | +$51.3K | 0.15% | 156 |
|
|
2017
Q3 | $1.37M | Buy |
7,204
+29
| +0.4% | +$5.52K | 0.14% | 157 |
|
|
2017
Q2 | $1.35M | Buy |
7,175
+18
| +0.3% | +$3.23K | 0.14% | 159 |
|
|
2017
Q1 | $1.18M | Buy |
7,157
+416
| +6% | +$66.2K | 0.13% | 165 |
|
|
2016
Q4 | $969K | Sell |
6,741
-788
| -10% | -$106K | 0.11% | 172 |
|
|
2016
Q3 | $943K | Sell |
7,529
-517
| -6% | -$66.8K | 0.11% | 167 |
|
|
2016
Q2 | $1.06M | Buy |
8,046
+202
| +3% | +$27.6K | 0.13% | 162 |
|
|
2016
Q1 | $1.09M | Buy |
7,844
+410
| +6% | +$54.8K | 0.13% | 156 |
|
|
2015
Q4 | $1.04M | Buy |
7,434
+498
| +7% | +$68.6K | 0.13% | 151 |
|
|
2015
Q3 | $971K | Buy |
6,936
+290
| +4% | +$43.6K | 0.13% | 149 |
|
|
2015
Q2 | $1.09M | Buy |
6,646
+70
| +1% | +$11.2K | 0.14% | 150 |
|
|
2015
Q1 | $1.01M | Sell |
6,576
-52
| -0.8% | -$7.4K | 0.13% | 154 |
|
|
2014
Q4 | $833K | Sell |
6,628
-142
| -2% | -$17.5K | 0.1% | 162 |
|
|
2014
Q3 | $810K | Sell |
6,770
-130
| -2% | -$14.9K | 0.11% | 160 |
|
|
2014
Q2 | $743K | Sell |
6,900
-430
| -6% | -$44.3K | 0.1% | 168 |
|
|
2014
Q1 | $730K | Hold |
7,330
| – | – | 0.1% | 165 |
|
|
2013
Q4 | $677K | Buy |
7,330
+40
| +0.5% | +$3.55K | 0.1% | 166 |
|
|
2013
Q3 | $610K | Sell |
7,290
-765
| -9% | -$65.6K | 0.1% | 164 |
|
|
2013
Q2 | $659K | Buy |
+8,055
| New | +$603K | 0.11% | 159 |
|
Other funds holding ELV
Dowling & Yahnke's ELV Position: Q3 2022 in Review
Dowling & Yahnke increased its Elevance Health (ELV) stake by 1.1% in Q3 2022, buying an estimated $64.1K and bringing the position to 12,014 shares worth $5.46M. The position accounts for 0.25% of the portfolio, ranked #97.
Dowling & Yahnke first reported a position in ELV in Q2 2013 and has held it in 36 quarters since. The position peaked at $5.84M in Q1 2022. 1,446 funds tracked by Wall St. Rank hold ELV as of Q3 2022.
- Dowling & Yahnke held 12,014 shares of Elevance Health worth $5.46M as of Q3 2022.
- Dowling & Yahnke bought 134 Elevance Health shares in Q3 2022, an estimated $64.1K.
- Elevance Health made up 0.25% of Dowling & Yahnke's portfolio in Q3 2022, its #97 holding.
- Dowling & Yahnke first reported a position in Elevance Health in Q2 2013 and has held it in 36 quarters since.
- Dowling & Yahnke's Elevance Health position peaked at $5.84M in Q1 2022.
- 1,446 funds tracked by Wall St. Rank held Elevance Health as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.